Search Results - "Claggett, Brian"

Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial.

Authors: Cunningham, Jonathan W. Claggett, Brian L. Vaduganathan, Muthiah et al.

Source: European Journal of Heart Failure. Aug2025, Vol. 27 Issue 8, p1487-1491. 5p.

Finerenone in Heart Failure with Preserved Ejection Fraction: THE AUTHORS REPLY.

Authors: Solomon, Scott D. Claggett, Brian McMurray, John J. V.

Source: New England Journal of Medicine. 1/16/2025, Vol. 392 Issue 3, p308-310. 3p.

Application of a transthyretin amyloid cardiomyopathy score to heart failure with mildly reduced or preserved ejection fraction.

Authors: Inciardi, Riccardo M. Vaduganathan, Muthiah Claggett, Brian et al.

Source: European Journal of Heart Failure. Dec2025, Vol. 27 Issue 12, p3012-3016. 5p.

Visit‐to‐visit changes in heart rate in heart failure: A pooled participant‐level analysis of the PARADIGM‐HF and PARAGON‐HF trials.

Authors: Lu, Henri Claggett, Brian L. Packer, Milton et al.

Source: European Journal of Heart Failure. Jan2025, Vol. 27 Issue 1, p60-68. 9p.

Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial.

Authors: Schou, Morten Claggett, Brian Miao, Zi Michael et al.

Source: European Journal of Heart Failure. Jan2024, Vol. 26 Issue 1, p130-139. 10p.

Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial.

Authors: Pabon, Maria Claggett, Brian L. Wang, Xiaowen et al.

Source: European Journal of Heart Failure. Sep2023, Vol. 25 Issue 9, p1663-1670. 8p. 3 Charts, 3 Graphs.

Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial.

Authors: Vaduganathan, Muthiah Claggett, Brian L. Lam, Carolyn S.P. et al.

Source: European Journal of Heart Failure. Jun2024, Vol. 26 Issue 6, p1324-1333. 10p.

Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.

Authors: Jering, Karola S. Claggett, Brian Pfeffer, Marc A. et al.

Source: European Journal of Heart Failure. Jun2021, Vol. 23 Issue 6, p1040-1048. 9p. 2 Diagrams, 5 Charts.

Anaemia in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial.

Authors: Chimura, Misato Yang, Mingming Henderson, Alasdair D. et al.

Source: European Journal of Heart Failure. Nov2025, Vol. 27 Issue 11, p2301-2312. 12p.

Effects of dapagliflozin on heart failure hospitalizations according to severity of inpatient course: Insights from DELIVER and DAPA‐HF.

Authors: Chatur, Safia Kondo, Toru Claggett, Brian L. et al.

Source: European Journal of Heart Failure. Aug2023, Vol. 25 Issue 8, p1364-1371. 8p. 5 Graphs.

Geographic differences in patients with acute myocardial infarction in the PARADISE‐MI trial.

Authors: Butt, Jawad H. Claggett, Brian L. Miao, Zi M. et al.

Source: European Journal of Heart Failure. Aug2023, Vol. 25 Issue 8, p1228-1242. 15p. 4 Charts, 5 Graphs, 2 Maps.

Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF.

Authors: Wang, Xiaowen Vardeny, Orly Claggett, Brian et al.

Source: European Journal of Heart Failure. Jan2025, Vol. 27 Issue 1, p96-106. 11p.

Recurrent venous thromboembolism and vaginal estradiol in women with prior venous thromboembolism: A nested case–control study.

Authors: Eckert‐Lind, Camilla Meaidi, Amani Claggett, Brian et al.

Source: European Journal of Haematology. Dec2024, Vol. 113 Issue 6, p745-750. 6p.

In‐hospital course of patients with heart failure with improved ejection fraction in the DELIVER trial.

Authors: Pabon, Maria A. Vaduganathan, Muthiah Claggett, Brian L. et al.

Source: European Journal of Heart Failure. Dec2024, Vol. 26 Issue 12, p2532-2540. 9p.

Association of post‐vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high‐risk cardiovascular disease: the INVESTED trial.

Authors: Peikert, Alexander Claggett, Brian L. Kim, KyungMann et al.

Source: European Journal of Heart Failure. Feb2023, Vol. 25 Issue 2, p299-310. 12p. 1 Diagram, 3 Charts, 3 Graphs.

Bayesian and Frequentist Stratified Analysis of Treatment Effects with Survival Data in Comparative Trials.

Authors: Paydarfar, Daniel Tian, Lu Claggett, Brian L. et al.

Source: Statistics in Biopharmaceutical Research. Apr2026, p1-9. 9p. 5 Illustrations, 2 Charts.

Sacubitril/valsartan reduces incident anaemia and iron therapy utilization in heart failure: The PARAGON‐HF trial.

Authors: Lu, Henri Claggett, Brian L. Packer, Milton et al.

Source: European Journal of Heart Failure. Jan2025, Vol. 27 Issue 1, p85-95. 11p.

The efficacy of finerenone on hierarchical composite endpoint analysed using win statistics in patients with heart failure and mildly reduced or preserved ejection fraction: A prespecified analysis of FINEARTS‐HF.

Authors: Kondo, Toru Jhund, Pardeep S. Henderson, Alasdair D. et al.

Source: European Journal of Heart Failure. Aug2025, Vol. 27 Issue 8, p1459-1471. 13p.

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial.

Authors: Chatur, Safia Claggett, Brian L. Vardeny, Orly et al.

Source: European Journal of Heart Failure. Jan2023, Vol. 25 Issue 1, p87-94. 8p. 1 Chart, 5 Graphs.

Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant‐level pooled analysis of DAPA‐HF and DELIVER.

Authors: Peikert, Alexander Vaduganathan, Muthiah Claggett, Brian L. et al.

Source: European Journal of Heart Failure. Apr2024, Vol. 26 Issue 4, p912-924. 13p.